This news release from the Food and Drug Administration (FDA) announces the agency’s recent approval of a new drug marketed as Nuplazid (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease (PD). The release leaves several crucial questions unanswered. We’re not told how much the drug will cost or how significant is the improvement offered by Nuplazid over placebo. A recent article in Stat that summarized an FDA panel’s recommendation to approve the drug, which the FDA followed, found that “In the pivotal trial behind Acadia’s marketing application, Nuplazid showed only modest improvements over placebo, and was tested in a way that makes it difficult to compare against other treatments.”
A public memo from the FDA on Nuplazid seems to suggest for about every two patients who are expected to benefit greatly from Nuplazid, another patient will suffer a significant side effect.
The release provides very little quantitative information but spends a great deal of time explaining the many symptoms of PD.
About 40 to 50 percent of PD patients experience some form of psychosis, ranging from mild hallucinations to severe paranoid delusions. Medications used to treat PD tremors are considered the top risk factor for developing psychosis. Other risk factors are advanced age and severity of the disease as well as cognitive decline. Because PD patients are at risk of developing new side effects with the addition of new drugs, any news of an improved anti-psychotic with fewer side effects would be welcome news. It’s unclear what the newly approved drug Nuplazid, supposedly developed specifically for PD psychosis, has over existing generic drugs used to reduce or manage psychotic symptoms.
The news release makes no mention of Nuplazid’s cost. An online search for the anticipated cost of the drug revealed only that market analysts predict the drug will reach blockbuster status — meaning it will have sales of at least $1 billion. The drug will no doubt be much costlier than competing generic anti-psychotics.
The release doesn’t quantify any benefits. We’re only told that, compared to a placebo, Nuplazid decreases the frequency and/or severity of hallucinations and delusions. But we aren’t given any actual numbers on how significant this improvement is. There is no information given about the significance of the results.
The release notes that Nuplazid has a “Boxed Warning alerting health care professionals about an increased risk of death associated with the use of these drugs to treat older people with dementia-related psychosis.” Other harms observed in the very brief (6-week) trial are swelling due to the accumulation of excessive fluid in the tissue, nausea and confusion. The release would have been stronger had it given us an idea of how common or rare these side effects are.
The release states that Nuplazid’s effectiveness was demonstrated in a six-week clinical trial of 199 participants. “Nuplazid was shown to be superior to placebo in decreasing the frequency and/or severity of hallucinations and delusions without worsening the primary motor symptoms of Parkinson’s disease,” according to the release.
The small study size and brief length of the trial are concerns that the release could have called attention to. The FDA has approved many drugs that underwent far more extensive clinical trials that were later pulled from the market due to adverse events. We already noted above under benefits that the release provides little in the way of quantification of the trial results. We are also disappointed that the release didn’t reference where the trial was published in a peer-reviewed journal so that people who wanted to could do an individual assessment of the study results.
The news release doesn’t engage in disease mongering. The release reports that 50,000 new cases of PD are diagnosed each year and that hallucinations or delusions are said to occur in as many as 50 percent of patients with PD at some point during their illness. That’s useful context.
The news release tells us Nuplazid is marketed and funded by Acadia Pharmaceuticals.
The only alternative mentioned in the news release is the placebo used for comparison in the clinical trial. What about other treatment methods? According to patient advocacy groups, other government websites and review articles, there are numerous alternatives in use for treating PD-related hallucinations and delusions. Among them, according to the University of Florida College of Medicine:
The news release is reporting FDA’s recent approval of Nuplazid so it’s understood the drug isn’t available now. Ideally, for patients’ sake, the news release would have mentioned the company’s announced roll-out plans.
According to a company news release, the firm intends to launch the drug in June 2016.
The news release states that this is the “first drug approved to treat hallucinations and delusions associated with psychosis experienced by some people with Parkinson’s disease.”
There is no evidence of unjustifiable language in the news release.